First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer

Journal:

The New England Journal of Medicine

Published:

2026-04-16

DOI:

10.1056/nejmoa2516969

Affiliations:

26

Authors:

24

Go to article

Institutions	Authors	Share
Boehringer Ingelheim Pharmaceuticals, Inc., United States of America (USA)	2.000000	0.08
Guangdong Academy of Medical Sciences (Guangdong Provincial People’s Hospital), China	2.000000	0.08
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany	2.000000	0.08
Netherlands Cancer Institute (NKI), Netherlands	1.500000	0.06
Henan Cancer Hospital, ZZU, China	1.000000	0.04
Hospital Universitario 12 de Octubre, Spain	1.000000	0.04
National Cancer Center Hospital, Japan	1.000000	0.04
Bellvitge Biomedical Research Institute (IDIBELL), Spain	1.000000	0.04
National Center for Tumor Diseases Dresden (NCT Dresden), Germany	1.000000	0.04
Samsung Medical Center (SMC), South Korea	1.000000	0.04
University Hospital of Cologne, Germany	1.000000	0.04
National Cancer Center Hospital East, Japan	1.000000	0.04
National University Cancer Institute (NCIS), Singapore	1.000000	0.04
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA)	1.000000	0.04
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.04
Boehringer Ingelheim International GmbH, Germany	1.000000	0.04
Institut du Thorax Curie-Montsouris, France	0.500000	0.02
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02
University of Versailles Saint-Quentin-en-Yvelines (UVSQ), France	0.500000	0.02
Leiden University Medical Center (LUMC), Netherlands	0.500000	0.02
Fred Hutchinson Cancer Center, United States of America (USA)	0.500000	0.02
University of Washington (UW), United States of America (USA)	0.500000	0.02
Institute Gustave-Roussy (IGR), France	0.500000	0.02
University of Paris-Saclay, France	0.500000	0.02
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.02

Interested in Oncology and Carcinogenesis?